We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Changes to Manufacturing Practices Should Accelerate Drug Development, Gottlieb Says
Changes to Manufacturing Practices Should Accelerate Drug Development, Gottlieb Says
April 10, 2006
Inadequate manufacturing processes are a main reason for slowdowns in the drug pipeline, according to a senior FDA official who notes that solving the problem will require greater emphasis by industry and changes to the agency’s good manufacturing practices (GMP) regulations.